Pα+ Psychedelic Bulletin #210: Compass minimal support model debate, ketamine comparison, and Reunion RE104 update

Pα+ Psychedelic Bulletin #210 focuses on major industry and research themes from a Stockholm dispatch, including Compass Pathways' argument for a “minimal support model” in psychedelic clinical trials. Compass CMO Guy Goodwin frames re-medicalising the psychedelic experience as a regulatory necessity, responding to critiques about unblinding, placebo and nocebo effects, and the claim that outcomes are driven by psychotherapy rather than the drug. He highlights protocol fidelity measurement and quantified therapist behavior to position the support as consistent and non-psychotherapy. The bulletin also covers an IV ketamine vs intranasal esketamine retrospective comparison, plus Reunion’s advancement of RE104 for adjustment disorder. It adds related pipeline context, including Mindstate completing Phase I and beginning a fixed-dose combination program, and it surfaces additional headlines such as New York Assembly discussions of psilocybin.